|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang N, Song WX, Luo J, Haydon RC and He
TC: Osteosarcoma development and stem cell differentiation. Clin
Orthop Relat Res. 466:2114–2130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Broadhead ML, Clark JC, Myers DE, Dass CR
and Choong PF: The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21(Suppl 7): vii320–vii325. 2010.PubMed/NCBI
|
|
6
|
Corradi D, Wenger DE, Bertoni F, Bacchini
P, Bosio S, Goldoni M, Unni KK, Sim FH and Inwards CY: Multicentric
osteosarcoma: Clinicopathologic and radiographic study of 56 cases.
Am J Clin Pathol. 136:799–807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lussier DM, O'Neill L, Nieves LM, McAfee
MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P and
Blattman JN: Enhanced T-cell immunity to osteosarcoma through
antibody blockade of PD-1/PD-L1 interactions. J Immunother.
38:96–106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gorlick R: Current concepts on the
molecular biology of osteosarcoma. Cancer Treat Res. 152:467–478.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mirabello L, Pfeiffer R, Murphy G, Daw NC,
Patiño-Garcia A, Troisi RJ, Hoover RN, Douglass C, Schüz J, Craft
AW and Savage SA: Height at diagnosis and birth-weight as risk
factors for osteosarcoma. Cancer Causes Control. 22:899–908. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J and Randall RL:
miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O'Connell RM, Rao DS and Baltimore D:
microRNA regulation of inflammatory responses. Annu Rev Immunol.
30:295–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reid G, Kirschner MB and van Zandwijk N:
Circulating microRNAs: Association with disease and potential use
as biomarkers. Crit Rev Oncol Hematol. 80:193–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K,
Ren G, Su T, Pan Y, Feng B, et al: MiR-150 promotes gastric cancer
proliferation by negatively regulating the pro-apoptotic gene EGR2.
Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baraniskin A, Kuhnhenn J, Schlegel U, Chan
A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A,
Schmiegel W, et al: Identification of microRNAs in the
cerebrospinal fluid as marker for primary diffuse large B-cell
lymphoma of the central nervous system. Blood. 117:3140–3146. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Turchinovich A, Weiz L, Langheinz A and
Burwinkel B: Characterization of extracellular circulating
microRNA. Nucleic Acids Res. 39:7223–7233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McDermott AM, Heneghan HM, Miller N and
Kerin MJ: The therapeutic potential of microRNAs: Disease
modulators and drug targets. Pharm Res. 28:3016–3029. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Olson EN: MicroRNAs as therapeutic targets
and biomarkers of cardiovascular disease. Sci Transl Med.
6:239ps32014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou X, Wei M and Wang W: MicroRNA-340
suppresses osteosarcoma tumor growth and metastasis by directly
targeting ROCK1. Biochem Biophys Res Commun. 437:653–658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bao YP, Yi Y, Peng LL, Fang J, Liu KB, Li
WZ and Luo HS: Roles of microRNA-206 in osteosarcoma pathogenesis
and progression. Asian Pac J Cancer Prev. 14:3751–3755. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jacob NK, Cooley JV, Yee TN, Jacob J,
Alder H, Wickramasinghe P, Maclean KH and Chakravarti A:
Identification of sensitive serum microRNA biomarkers for radiation
biodosimetry. PLoS One. 8:e576032013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Liu D, Chen X, Li J, Li L, Bian
Z, Sun F, Lu J, Yin Y, Cai X, et al: Secreted monocytic miR-150
enhances targeted endothelial cell migration. Mol Cell. 39:133–144.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bezman NA, Chakraborty T, Bender T and
Lanier LL: miR-150 regulates the development of NK and iNKT cells.
J Exp Med. 208:2717–2731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang N, Wei X and Xu L: miR-150 promotes
the proliferation of lung cancer cells by targeting P53. FEBS Lett.
587:2346–2351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park HR, Jung WW, Bacchini P, Bertoni F,
Kim YW and Park YK: Ezrin in osteosarcoma: comparison between
conventional high-grade and central low-grade osteosarcoma. Pathol
Res Pract. 202:509–515. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hunter KW: Ezrin, a key component in tumor
metastasis. Trends Mol Med. 10:201–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Khanna C, Wan X, Bose S, Cassaday R, Olomu
O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The
membrane-cytoskeleton linker ezrin is necessary for osteosarcoma
metastasis. Nat Med. 10:182–186. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Watanabe A, Tagawa H, Yamashita J, Teshima
K, Nara M, Iwamoto K, Kume M, Kameoka Y, Takahashi N, Nakagawa T,
et al: The role of microRNA-150 as a tumor suppressor in malignant
lymphoma. Leukemia. 25:1324–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yokobori T, Suzuki S, Tanaka N, Inose T,
Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H and Kuwano
H: MiR-150 is associated with poor prognosis in esophageal squamous
cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci.
104:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miao J, Wu S, Peng Z, Tania M and Zhang C:
MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects.
Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai H, Lin L, Cai H, Tang M and Wang Z:
Prognostic evaluation of microRNA-210 expression in pediatric
osteosarcoma. Med Oncol. 30:4992013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X
and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via
downregulation of the expression of Ezrin in F5M2 cells. Int J Mol
Med. 30:1013–1020. 2012.PubMed/NCBI
|
|
33
|
Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang
X and Wang L: Down-regulation of miR-183 promotes migration and
invasion of osteosarcoma by targeting Ezrin. Am J Pathol.
180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Neisch AL and Fehon RG: Ezrin, radixin and
moesin: Key regulators of membrane-cortex interactions and
signaling. Curr Opin Cell Biol. 23:377–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Clark JC, Dass CR and Choong PF: A review
of clinical and molecular prognostic factors in osteosarcoma. J
Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kafchinski LA and Jones KB: MicroRNAs in
osteosarcomagenesis. Adv Exp Med Biol. 804:119–127. 2014.
View Article : Google Scholar : PubMed/NCBI
|
